STOCKS TELEGRAPH

Tag: BPTH Stock

  • Bio-Path (BPTH) Stock Rides High On Promising Trial Results

    Bio-Path (BPTH) Stock Rides High On Promising Trial Results

    Positive study findings are causing Bio-Path Holdings, Inc. (NASDAQ: BPTH) stock price to rise an astounding 406.73% to $3.39. The results showed the promise of BP1001-A, a potential therapy for Type 2 diabetes that addresses obesity and associated metabolic issues.

    Bio-Path Coming Up With A Novel Approach

    In preclinical studies, BPTH observed that BP1001-A effectively raises insulin sensitivity by inhibiting the production of growth factor receptor-bound protein 2, or Grb2. This regulation mechanism has a beneficial effect on insulin signaling, which is necessary for glucose metabolism. According to scientific research, BP1001-A considerably reduces blood glucose levels in obese people with Type 2 diabetes via modulating the insulin pathway.

    The research’ main conclusions showed that BP1001-A increased the levels of phosphorylated AKT and phosphorylated FOXO-1 in both myoblast and hepatoma cells while decreasing the expression of the Grb2 protein in myoblast cells. These biochemical changes confirmed BP1001-A’s role in enhancing insulin-induced metabolic processes.

    Addressing an Unmet Medical Need

    Obesity and Type 2 diabetes remain interconnected global health challenges. Current weight-loss medications often fail to achieve significant results in patients with both conditions, underscoring the urgent need for innovative solutions. BP1001-A’s early success offers hope as an alternative method to lower blood glucose levels in obese patients with Type 2 diabetes, potentially filling a critical therapeutic gap.

    Path Forward: Clinical Trials in 2025

    To further confirm the effectiveness of BP1001-A, Bio-Path has started animal research and intends to start a first-in-human Phase 1 clinical study in 2025. Future pivotal studies will be made possible by these trials, which will evaluate the drug’s safety, pharmacokinetics, and ideal dosage.

    Bio-Path’s (BPTH) preclinical performance is accelerating the development of BP1001-A and highlighting its potential as a game-changing therapy for metabolic disorders. If effective, the treatment may represent a significant advancement in the treatment of Type 2 diabetes brought on by obesity, giving millions of people throughout the world fresh hope.

  • Bio-Path Holdings Inc (BPTH) Stock Has Surged 13.99% At $8.15 In current market Trading. Here’s What Happened

    Bio-Path Holdings, Inc., (BPTH) stock price increased by a staggering 13.99% after it announced the successful completion the safety run-in of Stage 2 of Phase 2 of its clinical study today, for the treatment of acute myeloid leukemia (AML). The safety run-in of Stage 2 of Phase 2 clinical trial consisted of six people effected with AML, who were evaluated and treated with a combination drugs providing a clean side effect profile and no toxicity.

    The efficacy signals in the data set also gave encouraging news about the treatment with five of six diagnosed AML patients showing clinical activity.

    The Phase 2 clinical trial currently consists of  21 patients present among all three groups. Accommodation of 19 patients in each group would provide an adequate analysis for comparative efficacy review compared with decitabine and venetoclax combination therapy. A positive efficacy result may mean an accelerated approval rate by FDA, with phase 2 of the trials being performed at up to 10 clinical sites.

    Corporate Bio-Path Holdings, Inc Highlights

    BPTH gained $13.0 Million from a Public Offering, consisting of 1,710,600 shares of common stock which was shared to the public for $7.60, Bio-path gaining a staggering $13M as financial surplus, before subtracting the fees and expense payable by the biotechnology company.

    Bio-Path also reported that their product was officially patented and given the title, “P-ethoxy nucleic acids for liposomal formulation.” The new patent protects the platform technology of the nanoparticle drug and gives all rights to BPTH for production.

    Conclusion

    If BPTH can deliver a drug enhancing the treatment of acute myeloid leukemia (AML), BPTH stock could have a serious capital gain. If the company has halted trials, BPTH shares could have an incredible plummet. Hence the clinical trials play a significant role in deciding the future valuation of the company.

  • 30 hot stocks trending in the pre-market session

    Naked Brand Group Limited (NAKD) stock plunged -4.92% to $0.1603 in the pre-market trading.

    Nano Dimension Ltd. (NASDAQ: NNDM)  shares are trading up 11.74% at $4.95 at the time of writing recently announced prices $100 million registered direct offering. Company’s 52-week ranged between $0.51 to $6.00. Analysts have a consensus price target of $8.

    BIO-key International Inc. (BKYI), a Security & Protection Services company, dropped about -6.14% at $2.75 in pre-market trading Monday after company recently announced that the Board of Directors has approved a 1-for-8 reverse stock split that is expected to become effective on November 20, 2020.

    Eiger BioPharmaceuticals Inc. (EIGR) stock moved up 9.67 percent to $11.0 in the pre-market trading following firm recently revealed that the U.S. Food and Drug Administration (FDA) has approved ZokinvyTM (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).

    Lexicon Pharmaceuticals Inc. (LXRX) is down more than -5.33% at $1.42 in pre-market hours Monday November 23, 2020. The stock had dropped over -3.23% to $1.50 in the last trading session.

    Despegar.com Corp. (DESP), a Travel Services company, dropped about -6.54% at $10.01 in pre-market trading Monday.

    Bristol-Myers Squibb Company (BMY) stock moved up 1.41 percent to $62.48 in the pre-market trading today following announcement of  a discovery collaboration with Bristol Myers Squibb Company (NYSE: BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.

    Niu Technologies (NIU) lost over -5.79% at $33.66 in pre-market trading Monday November 23, 2020 as the firm revealed changes to its board of directors and committees of the Board.

    Nxt-ID Inc. (NXTD) is up more than 8.36% at $0.389 in pre-market hours Monday November 23, 2020. The stock had dropped over -0.28% to $0.36 in the last trading session following the corporation said that it plans to adjourn the Annual Meeting of Stockholders, scheduled to be held on Monday, November 23, 2020 at 9:00 a.m. (Eastern Time), to Tuesday, November 24, 2020 at 9:00 a.m. (Eastern Time), to be held at the Company’s office at 288 Christian Street, Hangar C 2nd Floor, Oxford CT 06478.

    Before the trading started on November 23, 2020, Verb Technology Company Inc. (VERB) is up 9.26% to reach $1.18. It has been trading in a 52-week range of $0.78 to $2.64.

    CIIG Merger Corp. (CIIC) stock soared 13.29% to $19.26 in the pre-market trading.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) shares are trading up 8.89% at $9.8 at the time of writing. Company’s 52-week ranged between $3.26 to $11.35 after announced that it has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) – a rare disease for which there is no FDA-approved first-line therapy.

    Xunlei Limited (XNET) gained over 12.0% at $3.08 in pre-market trading Monday November 23, 2020.

    Amarin Corporation plc (AMRN) is down more than -9.74% at $4.17 in pre-market hours Monday November 23, 2020 after shared positive, statistically significant top-line results from Protocol Number EDPC003R01, a Phase 3 clinical trial of VASCEPA® (icosapent ethyl) conducted in China by Amarin partner, Edding. The stock had jumped over 1.76% to $4.62 in the last trading session.

    United Microelectronics Corporation (UMC) grew over 8.65% at $6.28 in pre-market trading today.

    Baozun Inc. (BZUN), a Internet Retail company, dropped about -4.82% at $39.9 in pre-market trading Monday. The firm today announced that its Board of Directors has appointed Mr. Arthur Yu, the Company’s current Vice President of Finance, as Chief Financial Officer (“CFO”), effective December 1, 2020.

    Pioneer Power Solutions Inc. (PPSI) stock moved up 10.49 percent to $4.32 in the pre-market trading.

    SPI Energy Co. Ltd. (SPI) gained over 8.79% at $10.4 in pre-market trading Monday November 23, 2020.

    Bio-Path Holdings Inc. (BPTH) is down more than -0.54% at $3.65 in pre-market hours Monday November 23, 2020 as a result of announcement that the enrollment and dosing of the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients. The stock had jumped over 9.88% to $3.67 in the last trading session.

    Before the trading started on November 23, 2020, Fuel Tech Inc. (FTEK) is up 19.69% to reach $1.52. It has been trading in a 52-week range of $0.30 to $2.05.

    Medigus Ltd. (MDGS) stock soared 8.48% to $3.07 in the pre-market trading after the firm announced its intention to enter into the electric vehicle and electric charging markets. Medigus signed a non-binding memorandum of understanding with the founders of EMuze to invest in a joint venture, NewCo, for the commercialization of EV micro-mobility vehicles for individual urban use, “last mile” and cargo delivery.

    GreenPower Motor Company Inc. (NASDAQ: GP) shares are trading up 11.34% at $24.54 at the time of writing as the news appeared that the Company has granted an aggregate of 300,000 incentive stock options with 100,000 stock options to each of Brendan Riley, Michael Sieffert and Fraser Atkinson. The stock options are subject to the approval of the TSX Venture Exchange and are exercisable for a period of five years at a price of US $20 per share. Company’s 52-week ranged between $0.82 to $23.45. Analysts have a consensus price target of $22.

    Check-Cap Ltd. (CHEK) grew over 7.1% at $0.38 in pre-market trading today.

    Mesoblast Limited (MESO), a Biotechnology company, rose about 9.8% at $15.13 in pre-market trading Monday after announcement of financial results for the third quarter and nine months ended September 30, 2020

    Titan Pharmaceuticals Inc. (TTNP) stock moved down -5.62 percent to $0.193 in the pre-market trading.

    The9 Limited (NCTY) gained over 21.45% at $3.68 in pre-market trading Monday November 23, 2020 as the company revealed that it will hold its annual general meeting of shareholders at the 17 Floor, No. 130 Wu Song Road, Hong Kou District, Shanghai 200080, People’s Republic of China on December 22, 2020 at 2:00 p.m., Shanghai time.

    Before the trading started on November 23, 2020, CPS Technologies Corporation (CPSH) is up 30.0% to reach $3.12. It has been trading in a 52-week range of $0.88 to $3.35.

    Canaan Inc. (CAN) stock soared 17.52% to $5.03 in the pre-market trading following the company plans to release its third quarter 2020 financial results before the market opens on Monday, November 30, 2020.

    Ferroglobe PLC (GSM), a Other Industrial Metals & Mining company, rose about 24.46% at $1.16 in pre-market trading Monday.

    Ideanomics Inc. (IDEX) stock moved up 37.01 percent to $2.11 in the pre-market trading after the company announced that it has increased its stake in California-based Solectrac, Inc. through a follow-on investment of an additional $1.3 million.

  • Bio-Path Holdings (NASDAQ: BPTH) Stock Skyrockets After Receiving Patent For Prexigebersen

    Bio-Path Holdings (NASDAQ: BPTH) Stock Skyrockets After Receiving Patent For Prexigebersen

    Bio-Path Holdings, Inc. (NASDAQ: BPTH) announced today that its lead product candidate, prexigebersen, in combination with front line cytidine analogues or Bcr-Abl tyrosine kinase inhibitors, has received the Notice of Allowance from the US Patent and Trademark office.

    US Patent and Trademark Office issued a Notice of Allowance to those candidates which USPTO believes that they are qualified for a patent. Before receiving the patent any candidate developed by the biotech companies is considered ‘Patent Pending’.

    Bio-Path Holdings’ prexigebersen is used to treat different types of cancers in combination with front-line therapies. Prexigebersen is a liposomal formulation holding the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

    The new patent labeled ‘Combination Therapy with Liposomal Antisense Oligonucleotides’ will enable the Bio-Path to use Prexigebersen for the treatment of cancer. This is the greatest achievement for the company as it strengthened its position in the market. Peter Nielsen, President, and CEO of Bio-Path said that this new patent not only protects the company’s core product portfolio but also provides protection in combination with established front-line therapies.

    Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares were trading up 25.18% at $5.12 at the time of writing on Thursday. It has a trading volume of 11.44 million as compared to the average volume of 161.74K. Bio-Path Holdings, Inc. (NASDAQ: BPTH) share price went from a low point of around $2.92 to briefly over $12.86 in the past 52 weeks. BPTH market cap has remained high, hitting $15.34 M at the time of writing.

    The biotechnology company is currently engaged in a Phase 2 clinical trial of prexigebersen along with decitabine to treat acute myeloid Leukemia (AML). This new patent it has received for the unique combination by USPTO will secure its ongoing trial and also provide aid to the company to bring new treatment options to patients with AML.